News
QNRX
4.840
+5.91%
0.270
Weekly Report: what happened at QNRX last week (0601-0605)?
Weekly Report · 1d ago
Quoin Receives Japan's MHLW Orphan Drug For QRX003 In Treating Netherton Syndrome
NASDAQ · 4d ago
Quoin Wins Japan Orphan Drug Status for QRX003
TipRanks · 5d ago
Quoin Pharmaceuticals QRX003 Receives Japan's Ministry Of Health, Labour And Welfare To Treat Netherton Syndrome
Benzinga · 5d ago
The Prognosis For Palvella Therapeutics
Seeking Alpha · 6d ago
Quoin Files IND For QRX003 To FDA In Treatment Of Peeling Skin Syndrome
NASDAQ · 6d ago
Quoin Pharmaceuticals submits QRX003 IND application to FDA
TipRanks · 06/02 14:36
Quoin Pharmaceuticals Pharmaceuticals Submits Investigational New Drug Application To FDA For Phase II Trial Of Peeling Skin Syndrome Treatment QRX003
Benzinga · 06/02 12:36
Weekly Report: what happened at QNRX last week (0525-0529)?
Weekly Report · 06/01 10:24
Weekly Report: what happened at QNRX last week (0518-0522)?
Weekly Report · 05/25 10:28
Weekly Report: what happened at QNRX last week (0511-0515)?
Weekly Report · 05/18 10:27
Weekly Report: what happened at QNRX last week (0504-0508)?
Weekly Report · 05/11 10:24
Quoin Pharmaceuticals (QNRX) Receives a Buy from Maxim Group
TipRanks · 05/08 15:55
Quoin Pharmaceuticals GAAP EPS of -$1.77 beats by $0.25
Seeking Alpha · 05/07 13:08
Quoin Pharmaceuticals Q1 EPS $(1.77) Misses $(1.72) Estimate
Benzinga · 05/07 12:32
Quoin Pharmaceuticals Price Target Announced at $30.00/Share by LUCID CAPITAL MARKETS
Dow Jones · 05/04 17:13
LUCID CAPITAL MARKETS Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $30
Benzinga · 05/04 17:04
Weekly Report: what happened at QNRX last week (0427-0501)?
Weekly Report · 05/04 10:22
Quoin Pharmaceuticals initiated with a Buy at Lucid Capital
TipRanks · 05/04 10:11
Quoin Pharma Plans To Initiate QRX009 Trial For Pachyonychia Congenita In Q3 2026; Stock Up
NASDAQ · 04/29 08:05
More
Webull provides a variety of real-time QNRX stock news. You can receive the latest news about Quoin Pharmaceuticals Ltd through multiple platforms. This information may help you make smarter investment decisions.
About QNRX
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.